Login / Signup

Long-Term, Real-World Safety and Efficacy of Teneligliptin: A Post-Marketing Surveillance of More Than 10,000 Patients with Type 2 Diabetes in Japan.

Takashi KadowakiMasakazu HanedaHiroshi ItoKazuyo SasakiMiyuki MatsukawaYuka Yamada
Published in: Advances in therapy (2019)
Japan Pharmaceutical Information Center clinical trials database identifier: Japic CTI-153047. Plain language summary available for this article.
Keyphrases
  • clinical trial
  • public health
  • autism spectrum disorder
  • randomized controlled trial
  • health information
  • healthcare
  • emergency department
  • adverse drug
  • phase ii
  • open label
  • double blind